AKT1 and cancer: While inhibiting MAPK6 (knockdown) and mTOR kinase activity (treatments using PP242 or INK128) each represses AKT phosphorylation and cancer cell growth, including anchorage-independent growth, treatment of both achieves the robust activity (Fig. 9 and fig.